Comparison of Screening Tools for Coronary Artery Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2006 by Aga Khan University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Wellcome Trust
Information provided by:
Aga Khan University
ClinicalTrials.gov Identifier:
NCT00383955
First received: October 3, 2006
Last updated: NA
Last verified: October 2006
History: No changes posted
  Purpose

Coronary artery disease (CAD) is a silent killer that may go undetected for years. It is the leading cause of death with no limitation to geographic boundaries accounting to about 16.7 million deaths world wide. Different studies have shown that South Asians populations are more prone to CAD where it is emerging as an epidemic. According to a study conducted in Karachi it is estimated that the overall prevalence of cardiovascular diseases in Pakistan is 26.9% with 23.7% in men and 30.0% in women. However tools for measuring CAD have not being adequately validated. This study is designed to develop screening tools and to determine test characteristics of Rose Questionnaire and Minnesota Coded ECG alone and in combination for diagnosis of CAD, using MPI as gold standard in Pakistan.


Condition
Cardiovascular Disease

Study Type: Observational
Study Design: Allocation: Random Sample
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Official Title: Comparison of Screening Tools for Coronary Artery Disease With Thallium Scintigraphy in Adult Population in Karachi.

Further study details as provided by Aga Khan University:

Estimated Enrollment: 450
Study Start Date: October 2006
Detailed Description:

Design: The proposed study is a cross sectional study of a population sample of 450 subjects aged > 40 years, and stratified by gender, residing in 12 randomly selected communities in Karachi, Pakistan.

The target population for this study would be drawn from an existing population based study entitled “Population based strategies for effective control of high blood pressure in Pakistan” (parent study), conducted by the primary supervisor and study director (TJ) in Karachi Subjects aged > 40 years would be eligible. Detailed information on each participant would be obtained from data collected for the parent study. This includes a) socio-demographic characteristics such as level of education, occupation, economic status, ethnicity, tobacco use , physical activity defined on the basis of International Physical Activity Questionnaire, dietary habits (food frequency questionnaire), family history of CAD, and the WHO standard Rose questionnaire (RQ) for coronary artery disease (CAD) (b) anthropometry including height, weight, waist and hip circumference (c) laboratory tests including fasting blood glucose, lipid profile, serum creatinine, and urine albumin to creatinine ratio. The community health workers (CHW) would administer RQ and obtain 12-lead EKG. They would give an appointment to subjects for MPI at the Aga Khan University Hospital. Each individual will then go through an exercise treadmill test (symptom limited Bruce or modified Bruce protocols) if able to walk, or pharmacological stress by the infusion of dobutamine or dipyridamole if unable to walk. The results of MPI study would be delivered to the subjects with interpretation by cardiologists, and referral to a physician (as appropriate).

Classification of Screening instruments: ECG will be Minnesota coded by two trained and independent coders, and discrepant reports will be resolved with a third independent coder. All cases of probable or possible CAD on Minnesota coding of ECG would be classified as “MC ECG positive for CAD” RQ will be coded according to standardized criteria into “positives for "angina" and "history of possible infarction" . Presence of either one would be classified as “RQ positive for CAD”.

  Eligibility

Ages Eligible for Study:   40 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult resident of Karachi residing in selected clusters
  2. Age > 40 years

Exclusion Criteria:

  1. Clinical Heart Failure
  2. Severe Disease e.g. Cancer
  3. Pregnant or lactating women
  4. People with limited mobility
  5. People not willing to participate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00383955

Contacts
Contact: Dr.Shazia S Abbas 92 21 4864860 ext - shazia.shehzad@aku.edu
Contact: Dr. Tazeen H Jafar, MD, MPH 92 21 4930051 ext 4818 tazeen.jafar@aku.edu

Locations
Pakistan
Aga Khan University, Hospital Recruiting
Karachi, Sindh, Pakistan
Sponsors and Collaborators
Aga Khan University
Wellcome Trust
Investigators
Study Director: Dr. Tazeen H Jafar, MD, MPH Aga Khan University
Principal Investigator: Dr. Shazia S Abbas Aga Khan University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00383955     History of Changes
Other Study ID Numbers: 078440/Z/05/Z
Study First Received: October 3, 2006
Last Updated: October 3, 2006
Health Authority: Pakistan: Medical Research Council

Additional relevant MeSH terms:
Cardiovascular Diseases
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on September 18, 2014